AstraZeneca Statistics
Share Statistics
AstraZeneca has 1.55B
shares outstanding. The number of shares has increased by 0.02%
in one year.
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | 0.02% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 206.14K, so 0.01% of the outstanding
shares have been sold short.
| Short Interest | 206.14K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.01% |
| Short Ratio (days to cover) | 66.54 |
Valuation Ratios
The PE ratio is 28.64 and the forward
PE ratio is null.
AstraZeneca's PEG ratio is
1.57.
| PE Ratio | 28.64 |
| Forward PE | n/a |
| PS Ratio | 3.73 |
| Forward PS | n/a |
| PB Ratio | 4.94 |
| P/FCF Ratio | 27.7 |
| PEG Ratio | 1.57 |
Financial Ratio HistoryEnterprise Valuation
AstraZeneca has an Enterprise Value (EV) of 226.13B.
| EV / Sales | 4.18 |
| EV / EBITDA | 14.65 |
| EV / EBIT | 19.06 |
| EV / FCF | 31.08 |
Financial Position
The company has a current ratio of 0.93,
with a Debt / Equity ratio of 0.74.
| Current Ratio | 0.93 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 1.95 |
| Debt / FCF | 4.14 |
| Interest Coverage | 5.95 |
Financial Efficiency
Return on Equity is 17.25% and Return on Invested Capital is 10.3%.
| Return on Equity | 17.25% |
| Return on Assets | 6.76% |
| Return on Invested Capital | 10.3% |
| Revenue Per Employee | $573,414.63 |
| Profits Per Employee | $74,602.33 |
| Employee Count | 94,300 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.93 |
Taxes
| Income Tax | 1.65B |
| Effective Tax Rate | 18.99% |
Stock Price Statistics
The stock price has increased by -11.46% in the
last 52 weeks. The beta is 0.18, so AstraZeneca's
price volatility has been higher than the market average.
| Beta | 0.18 |
| 52-Week Price Change | -11.46% |
| 50-Day Moving Average | 143.11 |
| 200-Day Moving Average | 145.77 |
| Relative Strength Index (RSI) | 45.47 |
| Average Volume (20 Days) | 1,713 |
Income Statement
In the last 12 months, AstraZeneca had revenue of 54.07B
and earned 7.04B
in profits. Earnings per share was 4.54.
| Revenue | 54.07B |
| Gross Profit | 43.87B |
| Operating Income | 10B |
| Net Income | 7.04B |
| EBITDA | 15.44B |
| EBIT | 10.37B |
| Earnings Per Share (EPS) | 4.54 |
Full Income StatementBalance Sheet
The company has 5.49B in cash and 30.11B in
debt, giving a net cash position of -24.63B.
| Cash & Cash Equivalents | 5.49B |
| Total Debt | 30.11B |
| Net Cash | -24.63B |
| Retained Earnings | 3.16B |
| Total Assets | 106.31B |
| Working Capital | -2.99B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 11.86B
and capital expenditures -4.59B, giving a free cash flow of 7.28B.
| Operating Cash Flow | 11.86B |
| Capital Expenditures | -4.59B |
| Free Cash Flow | 7.28B |
| FCF Per Share | 4.69 |
Full Cash Flow StatementMargins
Gross margin is 81.12%, with operating and profit margins of 18.5% and 13.01%.
| Gross Margin | 81.12% |
| Operating Margin | 18.5% |
| Pretax Margin | 16.07% |
| Profit Margin | 13.01% |
| EBITDA Margin | 28.55% |
| EBIT Margin | 18.5% |
| FCF Margin | 13.45% |
